Randomized controlled pilot trial of extended-release buprenorphine vs. sublingual buprenorphine-naloxone in rural settings (RXR): Study rationale and design
03/2026
Journal Article
Authors:
Mooney, L. J.;
Saxon, A. J.;
Black, M.;
Ober, A. J.;
Lewis, M.;
Walker, R.;
McCormack, J.;
Scheele, C.;
Hser, Y. I.
Journal:
Contemp Clin Trials
PMID:
41850520
URL:
https://www.ncbi.nlm.nih.gov/pubmed/41850520
Keywords:
Extended-release buprenorphine Medication for opioid use disorder Opioid use disorder Rural Sublingual buprenorphine
Abstract:
BACKGROUND: Rural communities continue to experience high overdose mortality rates and challenges retaining individuals with opioid use disorder (OUD) on medications for opioid use disorder (MOUD). The most recent formulation of injectable extended-release buprenorphine (XR-BUP) may improve treatment engagement and outcomes for people with OUD. OBJECTIVES: The RXR study (CTN-0102XR) aims to evaluate the feasibility of implementing XR-BUP in rural settings, acceptability of XR-BUP to clinic staff and patients, and effectiveness of XR-BUP compared with sublingual buprenorphine-naloxone (SL-BUP). STUDY DESIGN AND METHODS: This is an open-label randomized controlled trial (RCT) using intention-to-treat (ITT) analysis. Approximately 144 participants recruited from seven rural clinic sites will be randomized to receive XR-BUP or SL-BUP in a ratio of 2:1, and will receive study medication for 14 weeks. Participants in the XR-BUP condition will receive two weekly initiation dosages, followed by the target monthly dosage (128 mg) at Weeks 2, 6, and 10. Participants in the SL-BUP condition will receive medication on a similar schedule, with a target dose range of 16-24 mg/day. The main comparative effectiveness outcome measure is the number of monthly opioid negative urine drug screens (UDS) for non-prescribed opioids from Weeks 2-14. Feasibility and acceptability will be evaluated using mixed methods, combining participant survey and interview data from clinic administrators, providers, and patients. CONCLUSIONS: If demonstrated to be feasible and acceptable to participants and staff and there is evidence of effectiveness for people with OUD in reducing opioid use, XR-BUP may be considered an important option for addressing OUD in rural settings. CLINICALTRIALS: gov Identifier: NCT06023459.